Results 1 to 10 of about 2,143 (124)

Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant tuberculosis patients [PDF]

Scientific Reports
Pretomanid is a key component of the bedaquiline, pretomanid, linezolid with or without moxifloxacin (BPaL/M) regimen recommended for treatment of rifampicin-resistant tuberculosis (RR-TB).
Bern-Thomas Nyang’wa, Ilaria Motta, Ronelle Moodliar, Varvara Solodovnikova, Shakira Rajaram, Mohammed Rasool, Catherine Berry, Zhonghui Huang, Geraint Davies, David A.J. Moore, Frank Kloprogge   +10 more
doaj   +2 more sources

Pretomanid development and its clinical roles in treating tuberculosis

Journal of Global Antimicrobial Resistance, 2022
: Tuberculosis (TB) is the leading infectious cause of mortality worldwide. Despite the development of different antituberculosis drugs, managing resistant mycobacteria is still challenging.
Ginenus Fekadu, Tadesse Tolossa, Firomsa Bekele   +2 more
exaly   +3 more sources

A bactericidal tuberculosis drug regimen driven by inhibition of the terminal oxidases by pretomanid [PDF]

EMBO Molecular Medicine
Pretomanid is a unique anti-tuberculosis agent that inhibits both cell-wall synthesis and bioenergetics in Mycobacterium tuberculosis. While targeting the cell wall triggers a rapid bactericidal effect on replicating mycobacteria, the release of nitric ...
Nurlilah Ab Rahman, Samsher Singh, Thomas Wiggins, May Delos Santos, Garrett C Moraski, Marvin J Miller, Michael Berney, Kevin Pethe   +7 more
doaj   +2 more sources

In vitro and in vivo activity of omadacycline against Mycobacterium tuberculosis [PDF]

Frontiers in Microbiology
The bedaquiline (B), pretomanid (Pa), and linezolid (L) (BPaL) regimen is highly effective for drug-resistant tuberculosis (TB) but is limited by linezolid-associated toxicities, including myelosuppression and peripheral neuropathy.
Shahebraj Khan, Duc Nguyen, Dejan Nikolic, Baojie Wan, Akil Hossain, Mallique Qader, Sanghyun Cho, Scott G. Franzblau, Gauri S. Shetye   +8 more
doaj   +2 more sources

Efficacy of PBTZ169 and pretomanid against Mycobacterium avium, Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum in BALB/c mice models

Frontiers in Cellular and Infection Microbiology, 2023
ObjectivesWe aimed to evaluate the activity of PBTZ169 and pretomanid against non-tuberculous mycobacteriosis (NTM) in vitro and in vivo.MethodsThe minimum inhibitory concentrations (MICs) of 11 antibiotics, against slow-growing mycobacteria (SGMs) and ...
Weiyan Zhang, Lei Fu
exaly   +3 more sources

Resistance to Linezolid and Pretomanid in the Era of Modern Drug-Resistant Tuberculosis Treatment in South Africa: A Systematic Review and Meta-Analysis [PDF]

Antibiotics
Background: The success of modern drug-resistant tuberculosis (DR-TB) regimens increasingly depends on linezolid (LZD) and pretomanid (Pa), yet the emergence of resistance to these critical agents threatens to reverse recent treatment advances, with ...
Kabelo Gabriel Kaapu, Vukosi Treasure Makondo, Emilyn Costa Conceição, Ivy Rukasha   +3 more
doaj   +2 more sources

Bedaquiline, Pretomanid, Linezolid, and Moxifloxacin: Mechanisms of Action, Drug Interactions, Adverse Effects and Use in Special Situations [PDF]

Microorganisms
Tuberculosis (TB) remains a critical global public health challenge, requiring therapeutic strategies that ensure high cure rates while minimizing bacillary transmission.
Marcos Abdo Arbex
doaj   +2 more sources

High efficacy of BPaL among patients infected with Mycobacterium tuberculosis lineage 1 in the Philippines [PDF]

IJTLD Open
BACKGROUND: WHO recommends the bedaquiline–pretomanid–linezolid regimen with/without moxifloxacin (M) (BPaL/M) for the treatment of multidrug- or rifampicin-resistant TB.
I. Flores, M.A.A. Tujan, R. Basilio, T.J.R. Dizon, D.R Lim, L.T. Reyes, R.V.A.G. Reyes, S. Rojas, A.K. Valencia, J.B. Capin, V. Mirtskhulava, A.G. Palparan, C. Cabalitan, P.J. Carpin, C. Malbacias, J.S. Lee, A. Gebhard, M. Quelapio, J. Timm   +18 more
doaj   +2 more sources

Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application [PDF]

BMJ Open Respiratory Research
Multidrug-resistant tuberculosis (MDR-TB) is a global public health threat associated with high mortality and challenging treatment regimens. The UK, like many countries, faces a growing incidence of MDR-TB, with 105 (1.9% of all notified cases) treated ...
Onn Min Kon, Mark Gilchrist, Toby Capstick, Aneeka Chavda, Christabelle Chen   +4 more
doaj   +2 more sources

Whole-Genome Sequencing and Phenotypic Drug Susceptibility Testing of Bedaquilin, Delamanid, Pretomanid, and Linezolid in Drug-Resistant Mycobacterium tuberculosis from a Single Institute in South Korea [PDF]

Pathogens
Multidrug-resistant tuberculosis is a major global health concern. Newer agents, including bedaquiline (BDQ), delamanid (DLM), pretomanid (PMD), and linezolid (LZD), are essential for treatment; however, the resistance mechanisms of these drugs remain ...
Hyun-Woo Choi, Yoo-Ree Kang, Eun-Soon Son, Kyungsik Choi, Myungsun Cho, Young Jin Kim, Seo A Lee, Jin Young Lee, Jee Hey Kim, Seon Joo Kang, Seung-Jung Kee, Jong Seok Lee, Hee Joo Lee   +12 more
doaj   +2 more sources